At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 With Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combination With Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
In Brief
A Phase 2 clinical trial evaluating ABT-450, ABT-072, and 5 other interventions for Hepatitis C and 3 related conditions. Completed, enrolled 74 participants across 26 sites in 2 countries.
Detailed Summary
This study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of multiple oral doses of ABT-450/ritonavir (r), ABT-333 (also known as dasabuvir), or ABT-072 in hepatitis C virus (HCV), genotype 1-infected, treatment-naïve adults.
Study Details
Timeline
Interventions
50 mg capsules co-administered with ritonavir
50 mg tablet
400 mg tablet
100 mg capsules co-administered with ABT-450
Syringe, 180 µg/0.5 mL for subcutaneous injections
200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level